Symbols / ESPR Stock $3.12 +0.00% Esperion Therapeutics, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NGM
ESPR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Sheldon L. Koenig M.B.A.
Exch · Country NGM · United States
Market Cap 803.19M
Enterprise Value 1.18B
Income -22.68M
Sales 403.14M
FCF (ttm) -52.59M
Book/sh -1.23
Cash/sh 0.65
Employees 294
Insider 10d —
IPO Jun 26, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 12.87
PEG —
P/S 1.99
P/B -2.53
P/C —
EV/EBITDA 19.57
EV/Sales 2.93
Quick Ratio 1.02
Current Ratio 1.54
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.11
EPS next Y 0.24
EPS Growth —
Revenue Growth 143.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-10
ROA 9.30%
ROE —
ROIC —
Gross Margin 56.07%
Oper. Margin 50.60%
Profit Margin -5.63%
Shs Outstand 257.43M
Shs Float 254.57M
Insider Own 0.68%
Instit Own 63.59%
Short Float 12.56%
Short Ratio 4.89
Short Interest 31.83M
52W High 4.18
vs 52W High -25.36%
52W Low 0.69
vs 52W Low 352.17%
Beta 0.91
Impl. Vol. 73.05%
Rel Volume 2.79
Avg Volume 9.18M
Volume 25.60M
Target (mean) $3.19
Tgt Median $3.16
Tgt Low $3.16
Tgt High $3.28
# Analysts 4
Recom Hold
Prev Close $3.12
Price $3.12
Change 0.00%
About

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.19
Mean price target
2. Current target
$3.12
Latest analyst target
3. DCF / Fair value
$-3.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.12
Low
$3.16
High
$3.28
Mean
$3.19

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-04 down Needham Buy → Hold —
2026-05-01 down HC Wainwright & Co. Buy → Neutral $3
2026-03-13 main Citizens Market Outperform → Market Outperform $5
2026-03-03 main Needham Buy → Buy $5
2025-11-25 init Piper Sandler — → Overweight $9
2025-09-19 reit HC Wainwright & Co. Buy → Buy $16
2025-06-17 reit HC Wainwright & Co. Buy → Buy $16
2025-05-07 main Needham Buy → Buy $4
2025-04-25 reit HC Wainwright & Co. Buy → Buy $16
2025-04-25 reit Needham Buy → Buy $5
2025-04-17 main Goldman Sachs Neutral → Neutral $3
2025-04-08 reit Needham Buy → Buy $5
2025-03-20 reit HC Wainwright & Co. Buy → Buy $16
2025-03-05 reit Citizens Capital Markets Market Outperform → Market Outperform $4
2025-03-04 reit HC Wainwright & Co. Buy → Buy $16
2025-02-11 reit JMP Securities Market Outperform → Market Outperform $4
2025-02-11 reit HC Wainwright & Co. Buy → Buy $16
2025-01-23 reit JMP Securities Market Outperform → Market Outperform $7
2025-01-23 reit HC Wainwright & Co. Buy → Buy $16
2025-01-22 reit HC Wainwright & Co. Buy → Buy $16
News
RSS: Latest ESPR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 HALLADAY BENJAMIN Chief Financial Officer — 6,424 $2.70 $17,377
2026-03-17 KOENIG SHELDON L Chief Executive Officer — 25,578 $2.72 $69,547
2026-03-17 LOOKER BENJAMIN Officer — 5,708 $2.70 $15,429
2026-03-13 HALLADAY BENJAMIN Chief Financial Officer — 247,430 $0.00 $0
2026-03-13 KOENIG SHELDON L Chief Executive Officer — 723,760 $0.00 $0
2026-03-13 LOOKER BENJAMIN Officer — 300,840 $0.00 $0
2026-01-20 LOOKER BENJAMIN General Counsel — 1,689 $2.88 $4,868
2025-12-17 HALLADAY BENJAMIN Chief Financial Officer — 7,337 $3.67 $26,905
2025-12-17 KOENIG SHELDON L Chief Executive Officer — 48,244 $3.67 $177,200
2025-12-17 LOOKER BENJAMIN General Counsel — 6,517 $3.67 $23,898
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
403.13
+21.31%
332.31
+185.66%
116.33
+54.14%
75.47
Operating Revenue
403.13
+21.31%
332.31
+185.66%
116.33
+54.14%
75.47
Cost Of Revenue
129.22
+88.37%
68.60
+58.55%
43.27
+60.44%
26.97
Reconciled Cost Of Revenue
129.22
+88.37%
68.60
+58.55%
43.27
+60.44%
26.97
Gross Profit
273.91
+3.87%
263.71
+260.92%
73.07
+50.63%
48.51
Operating Expense
213.64
+2.07%
209.31
-8.45%
228.63
+0.27%
228.01
Research And Development
47.85
+3.49%
46.24
-46.30%
86.11
-27.60%
118.93
Selling General And Administration
165.79
+1.66%
163.07
+14.42%
142.52
+30.66%
109.08
Total Expenses
342.86
+23.37%
277.91
+2.21%
271.90
+6.64%
254.98
Operating Income
60.27
+10.79%
54.40
+134.97%
-155.56
+13.34%
-179.50
Total Operating Income As Reported
60.27
+10.79%
54.40
+134.97%
-155.56
+13.34%
-179.50
EBITDA
63.87
+743.81%
7.57
+105.04%
-150.11
+14.88%
-176.35
Normalized EBITDA
63.87
+2.21%
62.49
+141.63%
-150.11
+14.88%
-176.35
Reconciled Depreciation
0.10
+66.67%
0.06
-61.59%
0.16
-67.20%
0.50
EBIT
63.76
+749.49%
7.51
+104.99%
-150.27
+15.03%
-176.85
Total Unusual Items
0.00
+100.00%
-54.92
0.00
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-54.92
0.00
0.00
Special Income Charges
0.00
+100.00%
-54.92
0.00
0.00
Other Special Charges
—
54.92
—
—
Net Income
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Pretax Income
-20.84
+59.72%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Net Non Operating Interest Income Expense
-84.60
-42.79%
-59.25
-0.47%
-58.98
-3.81%
-56.81
Interest Expense Non Operating
84.60
+42.79%
59.25
+0.47%
58.98
+3.81%
56.81
Net Interest Income
-84.60
-42.79%
-59.25
-0.47%
-58.98
-3.81%
-56.81
Interest Expense
84.60
+42.79%
59.25
+0.47%
58.98
+3.81%
56.81
Other Income Expense
3.49
+107.44%
-46.90
-986.34%
5.29
+99.51%
2.65
Other Non Operating Income Expenses
3.49
-56.49%
8.02
+51.62%
5.29
+99.51%
2.65
Tax Provision
1.84
0.00
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Net Income From Continuing Operation Net Minority Interest
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Net Income From Continuing And Discontinued Operation
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Net Income Continuous Operations
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Normalized Income
-22.68
-814.84%
3.17
+101.52%
-209.25
+10.45%
-233.66
Net Income Common Stockholders
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Diluted EPS
-0.11
+60.71%
-0.28
+86.21%
-2.03
+42.33%
-3.52
Basic EPS
-0.11
+60.71%
-0.28
+86.21%
-2.03
+42.33%
-3.52
Basic Average Shares
207.87
+11.05%
187.18
+81.54%
103.11
+55.26%
66.41
Diluted Average Shares
207.87
+11.05%
187.18
+81.54%
103.11
+55.26%
66.41
Diluted NI Availto Com Stockholders
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
465.89
+35.50%
343.82
+67.07%
205.80
-17.00%
247.94
Current Assets
462.57
+36.86%
338.00
+68.10%
201.06
-18.49%
246.68
Cash Cash Equivalents And Short Term Investments
167.85
+15.95%
144.76
+76.01%
82.25
-50.71%
166.86
Cash And Cash Equivalents
167.85
+15.95%
144.76
+76.01%
82.25
-34.08%
124.78
Other Short Term Investments
—
—
0.00
-100.00%
42.09
Receivables
140.19
+74.93%
80.14
+65.26%
48.49
+43.78%
33.73
Accounts Receivable
140.19
+74.93%
80.14
+65.26%
48.49
+43.78%
33.73
Inventory
105.12
+11.25%
94.49
+43.99%
65.62
+86.42%
35.20
Raw Materials
98.77
+16.77%
84.58
+36.67%
61.89
+133.04%
26.56
Work In Process
4.53
+22.18%
3.71
+114.76%
1.73
-73.61%
6.55
Finished Goods
1.82
-70.58%
6.20
+209.03%
2.00
-4.30%
2.10
Prepaid Assets
44.91
+210.80%
14.45
+7386.53%
0.19
-81.19%
1.03
Other Current Assets
4.50
+8.21%
4.16
-7.81%
4.51
-54.32%
9.87
Total Non Current Assets
3.32
-43.05%
5.82
+23.08%
4.73
+276.67%
1.26
Net PPE
3.26
-43.47%
5.77
+23.36%
4.67
+289.58%
1.20
Gross PPE
5.44
-30.63%
7.84
+17.26%
6.69
+78.27%
3.75
Accumulated Depreciation
-2.18
-5.06%
-2.07
-3.08%
-2.01
+21.13%
-2.55
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.14
+0.00%
2.14
+17.33%
1.82
-24.54%
2.42
Construction In Progress
0.19
0.00
—
—
Other Properties
2.92
-47.00%
5.51
+17.93%
4.67
+351.25%
1.04
Leases
0.19
+0.00%
0.19
+0.00%
0.19
-36.79%
0.30
Goodwill And Other Intangible Assets
0.06
+0.00%
0.06
+0.00%
0.06
+0.00%
0.06
Other Non Current Assets
—
—
—
—
Total Liabilities Net Minority Interest
767.85
+4.82%
732.54
+10.86%
660.79
+15.58%
571.72
Current Liabilities
300.81
+22.16%
246.23
+57.62%
156.22
+69.24%
92.31
Payables And Accrued Expenses
164.69
+37.16%
120.07
+1.33%
118.50
+49.31%
79.36
Payables
65.07
+25.98%
51.65
+62.84%
31.72
+37.66%
23.04
Accounts Payable
65.07
+25.98%
51.65
+62.84%
31.72
+37.66%
23.04
Current Accrued Expenses
99.63
+45.60%
68.42
-21.15%
86.78
+54.08%
56.32
Pensionand Other Post Retirement Benefit Plans Current
11.94
-6.27%
12.74
+18.29%
10.77
+18.96%
9.05
Current Debt And Capital Lease Obligation
2.10
-96.33%
57.32
+3590.66%
1.55
+304.43%
0.38
Current Debt
—
54.58
—
—
Other Current Borrowings
—
54.58
—
—
Current Capital Lease Obligation
2.10
-23.31%
2.74
+76.50%
1.55
+304.43%
0.38
Current Deferred Liabilities
34.48
+304.75%
8.52
-66.47%
25.40
+624.32%
3.51
Current Deferred Revenue
34.48
+304.75%
8.52
-66.47%
25.40
+624.32%
3.51
Other Current Liabilities
87.60
+84.08%
47.59
—
—
Total Non Current Liabilities Net Minority Interest
467.04
-3.96%
486.31
-3.62%
504.57
+5.25%
479.41
Long Term Debt And Capital Lease Obligation
250.13
+4.10%
240.29
-9.19%
264.62
+1.56%
260.56
Long Term Debt
249.48
+4.95%
237.72
-9.13%
261.60
+0.65%
259.90
Long Term Capital Lease Obligation
0.65
-74.59%
2.57
-14.90%
3.02
+354.14%
0.67
Non Current Deferred Liabilities
—
—
—
0.00
Non Current Deferred Revenue
—
—
—
0.00
Other Non Current Liabilities
216.91
-11.83%
246.02
+2.53%
239.95
+9.64%
218.84
Stockholders Equity
-301.96
+22.32%
-388.72
+14.57%
-454.99
-40.53%
-323.78
Common Stock Equity
-301.96
+22.32%
-388.72
+14.57%
-454.99
-40.53%
-323.78
Capital Stock
0.24
+25.00%
0.20
+66.10%
0.12
+57.33%
0.07
Common Stock
0.24
+25.00%
0.20
+66.10%
0.12
+57.33%
0.07
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
247.21
+24.95%
197.85
+64.59%
120.20
+57.00%
76.56
Ordinary Shares Number
245.22
+25.20%
195.85
+65.68%
118.21
+58.52%
74.57
Treasury Shares Number
1.99
+0.00%
1.99
+0.00%
1.99
+0.00%
1.99
Additional Paid In Capital
1,376.50
+8.63%
1,267.11
+10.26%
1,149.17
+7.28%
1,071.18
Retained Earnings
-1,623.71
-1.42%
-1,601.03
-3.34%
-1,549.28
-15.62%
-1,340.04
Gains Losses Not Affecting Retained Earnings
0.00
0.00
0.00
+100.00%
-0.00
Treasury Stock
55.00
+0.00%
55.00
+0.00%
55.00
+0.00%
55.00
Other Equity Adjustments
—
—
—
-0.00
Total Equity Gross Minority Interest
-301.96
+22.32%
-388.72
+14.57%
-454.99
-40.53%
-323.78
Total Capitalization
-52.49
+65.24%
-151.01
+21.92%
-193.40
-202.76%
-63.88
Working Capital
161.76
+76.28%
91.77
+104.65%
44.84
-70.95%
154.38
Invested Capital
-52.49
+45.57%
-96.43
+50.14%
-193.40
-202.76%
-63.88
Total Debt
252.23
-15.24%
297.60
+11.81%
266.17
+2.00%
260.95
Net Debt
81.63
-44.67%
147.53
-17.74%
179.35
+32.73%
135.12
Capital Lease Obligations
2.75
-48.13%
5.31
+16.14%
4.57
+335.94%
1.05
Net Tangible Assets
-302.02
+22.32%
-388.78
+14.56%
-455.05
-40.52%
-323.83
Tangible Book Value
-302.02
+22.32%
-388.78
+14.56%
-455.05
-40.52%
-323.83
Interest Payable
0.26
-79.17%
1.23
-96.60%
36.15
+38.60%
26.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.09
+44.65%
-23.65
+82.54%
-135.49
+22.50%
-174.83
Cash Flow From Continuing Operating Activities
-13.09
+44.65%
-23.65
+82.54%
-135.49
+22.50%
-174.83
Net Income From Continuing Operations
-22.68
+56.17%
-51.74
+75.27%
-209.25
+10.45%
-233.66
Depreciation Amortization Depletion
0.10
+66.67%
0.06
-61.59%
0.16
-67.20%
0.50
Depreciation
0.10
+66.67%
0.06
-61.59%
0.16
-67.20%
0.50
Depreciation And Amortization
0.10
+66.67%
0.06
-61.59%
0.16
-67.20%
0.50
Other Non Cash Items
14.26
-34.14%
21.65
-55.25%
48.38
+4.69%
46.21
Stock Based Compensation
9.87
-17.70%
11.99
+0.29%
11.96
-21.41%
15.21
Operating Gains Losses
—
54.92
—
—
Change In Working Capital
-14.64
+75.81%
-60.53
-542.63%
13.68
+505.43%
-3.37
Change In Receivables
-60.05
-89.74%
-31.65
-114.34%
-14.77
-36.78%
-10.79
Changes In Account Receivables
-60.05
-89.74%
-31.65
-114.34%
-14.77
-36.78%
-10.79
Change In Inventory
-10.63
+63.17%
-28.87
+5.11%
-30.42
-3669.76%
-0.81
Change In Prepaid Assets
-30.80
-121.52%
-13.90
-324.55%
6.19
+336.36%
1.42
Change In Payables And Accrued Expense
52.14
+69.43%
30.77
0.00%
30.77
+219.91%
9.62
Change In Accrued Expense
31.22
+70.23%
18.34
-16.99%
22.10
+450.09%
4.02
Change In Payable
20.92
+68.26%
12.43
+43.26%
8.68
+54.88%
5.60
Change In Account Payable
20.92
+68.26%
12.43
+43.26%
8.68
+54.88%
5.60
Change In Other Working Capital
25.96
+253.75%
-16.88
-177.11%
21.89
+879.18%
-2.81
Change In Other Current Liabilities
8.74
0.00
0.00
0.00
Investing Cash Flow
0.00
+100.00%
-0.32
-100.75%
42.50
+424.43%
8.10
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.32
-100.75%
42.50
+424.43%
8.10
Net PPE Purchase And Sale
0.00
+100.00%
-0.32
0.00
0.00
Purchase Of PPE
0.00
+100.00%
-0.32
0.00
0.00
Capital Expenditure
—
-0.32
—
—
Net Investment Purchase And Sale
0.00
0.00
-100.00%
42.50
+424.43%
8.10
Purchase Of Investment
—
0.00
0.00
+100.00%
-59.90
Sale Of Investment
0.00
0.00
-100.00%
42.50
-37.50%
68.00
Net Intangibles Purchase And Sale
—
—
—
—
Purchase Of Intangibles
—
—
—
—
Financing Cash Flow
36.18
-58.16%
86.48
+71.39%
50.46
+54.76%
32.61
Cash Flow From Continuing Financing Activities
36.18
-58.16%
86.48
+71.39%
50.46
+54.76%
32.61
Net Issuance Payments Of Debt
-54.91
-256.83%
35.01
0.00
0.00
Issuance Of Debt
0.00
-100.00%
245.10
0.00
0.00
Repayment Of Debt
-54.91
+73.86%
-210.09
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
245.10
0.00
0.00
Long Term Debt Payments
-54.91
+73.86%
-210.09
0.00
0.00
Net Long Term Debt Issuance
-54.91
-256.83%
35.01
0.00
0.00
Net Common Stock Issuance
88.00
-3.49%
91.19
+60.32%
56.88
-37.40%
90.85
Common Stock Payments
—
—
—
—
Cash Dividends Paid
0.00
0.00
0.00
0.00
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
10.35
-30.12%
14.81
+63.28%
9.07
0.00
Net Other Financing Charges
-7.26
+85.10%
-48.69
-231961.90%
0.02
+100.04%
-50.22
Changes In Cash
23.09
-63.06%
62.51
+247.00%
-42.53
+68.29%
-134.12
Beginning Cash Position
144.76
+76.01%
82.25
-34.08%
124.78
-51.80%
258.89
End Cash Position
167.85
+15.95%
144.76
+76.01%
82.25
-34.08%
124.78
Free Cash Flow
-13.09
+45.38%
-23.97
+82.31%
-135.49
+22.50%
-174.83
Interest Paid Supplemental Data
16.27
+43.35%
11.35
+7.05%
10.60
—
Income Tax Paid Supplemental Data
0.61
0.00
0.00
—
Amortization Of Securities
0.00
0.00
+100.00%
-0.41
-247.67%
0.28
Common Stock Issuance
88.00
-3.49%
91.19
+60.32%
56.88
-37.40%
90.85
Interest Paid CFF
0.00
+100.00%
-5.83
+62.39%
-15.51
-93.25%
-8.02
Issuance Of Capital Stock
88.00
-3.49%
91.19
+60.32%
56.88
-37.40%
90.85
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category